Orakle.

Live webinar · Continuing education · 1.0 AMA PRA Category 1 Credit

Reflections from the Early Gene Therapies for Hemophilia B.

TUESDAY, AUGUST 26 2025, 18.30 CET / 12:30 EST / 09:30 PST / 20:30 GST Gulf

Activity Overview. This activity equips healthcare teams to counsel, select, and monitor hemophilia B patients for gene therapy, an emerging treatment within their clinical scope.

Target Audience. This activity is designed for an audience of Physicians.

Get started

Learning objectives

  • 01

    Describe the long-term efficacy, safety, and durability of AAV5-FIX gene therapy in Hemophilia B

  • 02

    Apply patient selection criteria and counseling strategies for gene therapy in clinical practice

  • 03

    Implement appropriate monitoring and follow-up care for patient’s post-gene therapy to optimize outcomes

Faculty

  • Amit Nathwani MD

    Department of Hematology, University College London

  • Frank Leebeek MD

    Department of Hematology, Erasmus University Medical Center

  • Robert Klamroth MD

    Department of Internal Medicine and Coagulation Disorders, Vivantes Hospital

  • Moderator: Wolfgang Miesbach MD

    The Haemophilia Center, Frankfurt University Hospital